CIK Incorporating Safety Switch Devlopment Service

Safety Switch Systems Aid in CIK Development

CIK cell therapy, a promising approach in cancer treatment, involves engineering immune cells to target and eliminate cancer cells. While offering significant potential, there is a risk of off-target effects, potentially harming healthy tissues. Promisingly, the safety switch approach to engineering CIKs is expected to reduce this risk. These safety mechanisms enable the controlled deactivation of CIK cells, enhancing the safety profile of this therapy and ensuring its responsible clinical application. Therefore, it is a promising strategy that safety switch incorporation for CIK development to advance cancer cell therapeutics development.

Advantages of CIK Incorporating Safety Switch Development

• Broad anti-tumor activity
• Fewer side effects compared to traditional therapies.
• Minimal preparation time
• Enhances effectiveness when combined with other treatments.
• Potential for long-term immunity
• Ease of administration

Fig.1 Combination strategies for effective CIK cell therapy.^1,3

CIK Incorporating Safety Switch Development Service at Creative Biolabs

Creative Biolabs provides a comprehensive service to develop robust safety switches-incorporated CIKs to administrate their anti-tumor efficacy. Our services encompass safety switch gene design, cell isolation, expansion, genetic modification, and characterization. Leveraging advanced gene editing and mRNA-based technologies, we introduce safety switch genes into CIK cells, enabling precise control and deactivation of these cells in the event of unintended side effects.

We provide a comprehensive suite of advanced suicide gene systems, encompassing metabolism-based, dimerization-induced, and antibody-mediated methods. Our rigorous quality assurance processes guarantee the reliable performance and safety of our engineered CIK cells. Furthermore, we specialize in pioneering CIK cell engineering techniques, including CAR-CIK, DC-CIK, and modified cytokine receptor-CIK, designed to enhance their therapeutic effectiveness. Through our cutting-edge technology platform, we are dedicated to offering top-tier, safety-integrated CIK cells to propel the progress of cancer immunotherapy.

Fig.2 CIK incorporating safety switch development service process.

Selective Suicide Gene Systems

The integration of suicide genes into cellular therapeutic products offers a promising approach to selectively eliminate gene-modified cells, thereby mitigating the risk of unintended collateral damage to surrounding tissues. The ideal suicide gene would provide an irreversible and specific mechanism to eliminate only the cells responsible for adverse events, ensuring the safety and efficacy of gene-modified cellular therapies. Here we provide a series of well-validated suicide gene systems for global customers to choose from:

• Dimerization inducing: inducible Caspase 9 (iCasp9); inducible FAS (iFAS)
• Metabolic-based: herpes-simplex-thymidine-kinase (HSV-TK); cytosine deaminase (CD)
• Therapeutic monoclonal antibody-mediated: CD20; c-myc; EGFR

Fig.3 MOA of the suicide gene systems.^2,3

Benefits for You

• Extensive CIK research experience.
• Selective safety switch systems.
• Stable cell engineering platforms.
• Personalized CIK engineering service.
• Diverse CIK engineering strategies.
• Reduced costs and accelerated timeline.
• State-of-the-art technologies incorporating.

Frequently Asked Questions

Q1: How to understand the safety switch?

A1: A safety switch is a genetically modified mechanism that selectively eliminates infused therapeutic cells, such as CIK cells, in the case of an unfavorable immune response or other unforeseen effects. This safety safeguard guarantees that these cells are removed quickly and permanently, reducing the risk of injury to the patient. An optimal safety switch should be extremely effective in depleting target cells while causing little harm to healthy tissues.

Q2: How about the characterization of safety switch-engineered CIK cells?

A2: Characterization of safety switch-engineered CIK cells is a critical step to ensure their safety and efficacy. This involves a comprehensive assessment of their phenotypic and genotypic properties, as well as their functional capabilities. Key parameters include evaluating cell surface marker expression, confirming transgene integration, assessing cytotoxicity and cytokine production, and conducting in vitro and in vivo safety and efficacy studies. In addition, rigorous quality control measures, including cell purity, viability, and mycoplasma contamination testing, are equally essential to maintain the quality and consistency of these engineered cells.

If you want to know more about our CIK incorporating safety switch development service, please don't hesitate to contact us.

References

1. Cappuzzello, Elisa, et al. "How can Cytokine-induced killer cells overcome CAR-T cell limits." Frontiers in Immunology 14 (2023): 1229540.
2. Jones, Benjamin S., et al. "Improving the safety of cell therapy products by suicide gene transfer." Frontiers in Pharmacology 5 (2014): 254.
3. Distributed under Open Access license CC BY 4.0, without modification.